Expanded Access of MK-3475 in Metastatic Melanoma Patients with Limited to No Treatment Options
What is the purpose of this trial?
This is an expanded access program (EAP) for participants who have progressed after prior systemic therapy including ipilimumab, and V-raf murine sarcoma viral oncogene homolog B1 (BRAF) inhibitor or mitogen-activated protein kinase (MEK) enzyme inhibitor when indicated. Participants cannot be eligible for or have participated in any pembrolizumab (MK-3475) clinical trial.
- Merck Sharp & Dohme
- Last Updated:
- Study HIC#: